A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.
Condition(s):Chronic Spontaneous UrticariaLast Updated:March 26, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Chronic Spontaneous UrticariaLast Updated:March 26, 2024Recruiting
Condition(s):Sore ThroatLast Updated:March 16, 2021Completed
Condition(s):Female Sexual Interest/Arousal DisorderLast Updated:November 24, 2023Suspended
Condition(s):Chronic Obstructive Pulmonary Disease (COPD)Last Updated:August 17, 2011Completed
Condition(s):SchizophreniaLast Updated:July 19, 2006Completed
Condition(s):Scar; Keloid; Hypertrophic Scar; CicatrixLast Updated:March 21, 2022Completed
Condition(s):Renal Disease; Depression; AnxietyLast Updated:August 20, 2019Completed
Condition(s):Parkinson’s Disease; Mild Cognitive ImpairmentLast Updated:January 8, 2016Completed
Condition(s):SARS-CoV-2 InfectionLast Updated:November 8, 2022Withdrawn
Condition(s):Pneumococcal DiseaseLast Updated:November 22, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.